New publications have provided more detailed examples of the platform's research utility and hinted at future clinical applications in immuno-oncology.
The partners will use the GeoMx Digital Spatial Profiler to identify new biomarkers in high-risk breast cancer and the nCounter to evaluate leukemia fusion testing.
Authors concluded that all three assays — Oncotype DX, EndoPredict, and Prosigna — met Canadian thresholds for cost-effectiveness and urged caution in considering the findings.
The deals with Covance, NeoGenomics Laboratories, and Navigate BioPharma Services aim to expand access to NanoString's PanCancer IO 360 Gene Expression Panel.
The researchers have used nCounter, an FDA-cleared platform from NanoString Technologies, to develop their gene expression assay for subtype classification.
The company reported total revenues of $27.7 million, with growth in its consumables business but a drop in instrument revenues from the prior year's first quarter.
Under the agreement, the companies will create a workflow integrating NanoString's GeoMx Digital Spatial Profiling instrument with Leica's Bond RX autostainer.
A genetic analysis of salmon scales collected over the course of a century points to a sharp decline in the number of fish returning each year to river in British Columbia, CBC reports.
